HLA-B7 Antibodies

Santa Cruz Biotechnology offers a broad range of HLA-B7 monoclonal antibodies for immunology and cell biology research. HLA-B7 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). HLA-B7 is a crucial component of the major histocompatibility complex (MHC) class I molecules, playing a significant role in the immune response by presenting peptide antigens to CD8+ T cells. HLA-B7 expression is vital for the recognition of infected or malignant cells, making it an important target in cancer immunotherapy and transplantation studies. Understanding HLA-B7 function and regulation can provide insights into immune evasion mechanisms and potential therapeutic strategies. Researchers can explore HLA-B7's role in antigen presentation and immune system regulation through various experimental approaches. Current investigations focus on HLA-B7's involvement in autoimmune disorders, transplant rejection, and cancer immunology. Santa Cruz Biotechnology monoclonal antibodies for HLA-B7 support researchers worldwide in advancing immunological discoveries and developing innovative therapeutic approaches.